Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

PubWeight™: 1.47‹?› | Rank: Top 5%

🔗 View Article (PMID 9816191)

Published in Clin Cancer Res on March 01, 1996

Authors

S J Knox1, M L Goris, K Trisler, R Negrin, T Davis, T M Liles, A Grillo-López, P Chinn, C Varns, S C Ning, S Fowler, N Deb, M Becker, C Marquez, R Levy

Author Affiliations

1: Departments of Radiation Oncology, Diagnostic Radiology, Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, California, 94305, USA.

Associated clinical trials:

First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (SYNFRIZZ) | NCT01469975

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma | NCT01207765

Articles citing this

The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov (2010) 2.23

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev (2008) 2.16

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A (2000) 1.81

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood (2009) 1.72

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging (2007) 1.71

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood (2008) 1.58

131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood (2005) 1.48

Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival. Oncotarget (2013) 1.40

Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. Br J Pharmacol (2009) 1.21

Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A (2003) 1.18

Cancer radioimmunotherapy. Immunotherapy (2011) 1.10

Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev (2008) 1.00

Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer (2010) 0.96

A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer (2009) 0.94

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood (2010) 0.93

Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy. J Med Chem (2007) 0.92

Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clin Med Res (2005) 0.91

Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies. Med Phys (2009) 0.89

Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. Cancer (2010) 0.88

Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood (2006) 0.87

Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma. Clin Cancer Res (2011) 0.84

Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells. Br J Cancer (2000) 0.84

Theranostic Imaging of Yttrium-90. Biomed Res Int (2015) 0.83

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica (2014) 0.81

Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc Natl Acad Sci U S A (2007) 0.81

Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol (2008) 0.81

EQPlanar: a maximum-likelihood method for accurate organ activity estimation from whole body planar projections. Phys Med Biol (2011) 0.76

Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma. Onco Targets Ther (2009) 0.76

Preparation & in vitro evaluation of (90) Y-DOTA-rituximab. Indian J Med Res (2016) 0.75

Imaging virus-associated cancer. Curr Pharm Des (2008) 0.75

Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling. Cancer Biother Radiopharm (2010) 0.75

Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan. Eur J Nucl Med Mol Imaging (2012) 0.75

Articles by these authors

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38

Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. J Cell Biol (1982) 14.41

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18

The large-scale separation of peroxisomes, mitochondria, and lysosomes from the livers of rats injected with triton WR-1339. Improved isolation procedures, automated analysis, biochemical and morphological properties of fractions. J Cell Biol (1968) 11.54

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40

Generation and analysis of 280,000 human expressed sequence tags. Genome Res (1996) 8.27

Two populations of Ia-like molecules on a human B cell line. J Immunol (1980) 7.68

The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90

The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43

An exploration of the sequence of a 2.9-Mb region of the genome of Drosophila melanogaster: the Adh region. Genetics (1999) 5.87

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59

'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biol (2000) 5.29

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 4.97

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med (1993) 4.91

A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (1990) 4.90

Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet (2000) 4.83

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol (1997) 4.32

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med (1996) 4.15

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med (1998) 4.13

A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology (1999) 4.10

The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings. Br J Psychiatry (1993) 3.95

Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78

Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. Proc Natl Acad Sci U S A (1981) 3.63

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res (1997) 3.55

Patterns of association with host and habitat: antibody reactive with Sin Nombre virus in small mammals in the major biotic communities of the southwestern United States. Am J Trop Med Hyg (1997) 3.46

Obliquity-paced Pliocene West Antarctic ice sheet oscillations. Nature (2009) 3.42

Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol (1994) 3.39

MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res (1997) 3.38

Picosecond kinetics of the initial photochemical electron-transfer reaction in bacterial photosynthetic reaction centers. Biochemistry (1985) 3.30

Polypeptide and phospholipid composition of the membrane of rat liver peroxisomes: comparison with endoplasmic reticulum and mitochondrial membranes. J Cell Biol (1982) 3.05

Large-scale reductions in speeding and accidents in Canada and Israel: a behavioral ecological perspective. J Appl Behav Anal (1985) 2.93

Characterization of lipid-laden aortic cells from cholesterol-fed rabbits. IV. Investigation of macrophage-like properties of aortic cell populations. Lab Invest (1979) 2.79

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med (1992) 2.73

Climatic and environmental patterns associated with hantavirus pulmonary syndrome, Four Corners region, United States. Emerg Infect Dis (1999) 2.73

CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell (1993) 2.73

Measuring client gains from staff-implemented programs. J Appl Behav Anal (1978) 2.72

Tacrine in Alzheimer's disease. Lancet (1991) 2.67

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med (1999) 2.67

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature (1993) 2.62

TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol (1990) 2.60

Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med (2000) 2.55

Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (1994) 2.53

Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method. J Histochem Cytochem (1980) 2.52

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 2.48

Complete genome sequence of the genetically tractable hydrogenotrophic methanogen Methanococcus maripaludis. J Bacteriol (2004) 2.47

Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am J Trop Med Hyg (1994) 2.42

Prospective study to determine clinical relevance of detection of pneumococcal DNA in sera of children by PCR. J Clin Microbiol (1998) 2.42

The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol (1999) 2.40

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol (1999) 2.36

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood (2001) 2.35

A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain (1988) 2.32

The neural system that bridges reward and cognition in humans: an fMRI study. Proc Natl Acad Sci U S A (2002) 2.26

Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A (2000) 2.24

Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol (1998) 2.21

Multicenter evaluation of the Cepheid Xpert methicillin-resistant Staphylococcus aureus (MRSA) test as a rapid screening method for detection of MRSA in nares. J Clin Microbiol (2009) 2.20

Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis (1999) 2.12

Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia (2003) 2.12

Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation. Br J Haematol (1998) 2.10

Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access. Arch Intern Med (1993) 2.10

Carbon monoxide re-breathing during low-flow anaesthesia in infants and children. Br J Anaesth (2010) 2.09

Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J Clin Microbiol (2009) 2.07

Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc Natl Acad Sci U S A (1978) 2.06

Barriers to breast and cervical cancer screening among Vietnamese-American women. Am J Prev Med (1997) 2.05

Hurthle cell carcinoma of the thyroid gland. A tumor of moderate malignancy. Cancer (1986) 2.04

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03

Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br J Psychiatry (1990) 2.01

Opening pathways to cancer screening for Vietnamese-American women: lay health workers hold a key. Prev Med (1999) 1.98

The monoclonality of human B-cell lymphomas. J Exp Med (1977) 1.97

Three genes coding for subunits of the membrane sector (F0) of the Escherichia coli adenosine triphosphatase complex. J Bacteriol (1981) 1.97

Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. Blood (1997) 1.96

A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 1.94

Lewy bodies and response to tacrine in Alzheimer's disease. Lancet (1994) 1.94

The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry (1989) 1.94

Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma. Cell (1986) 1.92

Impaired lymphocyte function in untreated Hodgkin's disease. N Engl J Med (1974) 1.91

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res (1999) 1.91

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1999) 1.91

A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 1.91

Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant (1999) 1.90

Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis (1995) 1.88

Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet (1993) 1.87

Accuracy of clinical diagnosis of Alzheimer's disease. BMJ (1990) 1.84

Cognitive performance in tests sensitive to frontal lobe dysfunction in the elderly depressed. Psychol Med (1996) 1.84

Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc Natl Acad Sci U S A (1992) 1.82

Mutation in the SPINK1 trypsin inhibitor gene, alcohol use, and chronic pancreatitis. JAMA (2001) 1.81

Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem (1995) 1.81

The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene (1997) 1.81

Early medical use of cannabis. Nature (1993) 1.80

An overview of the CERC ARTEMIS project. Proc Annu Symp Comput Appl Med Care (1995) 1.80